A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients
L5
L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients
1 other identifier
observational
48
1 country
1
Brief Summary
The purpose of this study is to determine whether L5, one of the Low Density Lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
November 5, 2010
CompletedFirst Posted
Study publicly available on registry
November 9, 2010
CompletedNovember 9, 2010
November 1, 2010
November 5, 2010
November 8, 2010
Conditions
Keywords
Study Arms (3)
Normal
Healthy population
CKD Patients
Chronic Kidney Disease, in Stage III-V
HD patients
End-stage renal disease patients undergoing hemodialysis
Eligibility Criteria
Residents in Taiwan, mostly in Taichung area
You may qualify if:
- clinical diagnosis of CKD
- clinical diagnosis of HD
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
China Medical University Hospital
Taichung, Taiwan, 404, Taiwan
Biospecimen
Blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 5, 2010
First Posted
November 9, 2010
Study Start
September 1, 2010
Last Updated
November 9, 2010
Record last verified: 2010-11